Any Questions? A Sober Look at MDMA.
Luke G. Petry, Monica Sharma, Aaron Wolfgang, David A. Ross, Joseph J. Cooper
Biol Psychiatry August 1, 2021 DOI: 10.1016/j.biopsych.2021.06.001 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractThe text critically examines the use of MDMA in therapeutic contexts, arguing that the current enthusiasm for MDMA-assisted therapy may overlook significant risks and methodological shortcomings. It questions the robustness of evidence supporting its efficacy for conditions like PTSD, highlighting issues such as small sample sizes, lack of long-term safety data, and potential for adverse effects. The author suggests that a sober, evidence-based evaluation is necessary before embracing MDMA as a treatment, emphasizing the need for rigorous research and caution against premature adoption.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy PTSD |
| Keywords | MDMA Therapy MDMA-Assisted Therapy Drug-assisted therapy Controlled therapeutic sessions |
| Citations | 4 |
| Key finding | Argues that MDMA carries significant risks including neurotoxicity and serotonin depletion, challenging the perception of it as a harmless drug. |
Abstract
Any Questions? A Sober Look at MDMA.